Study registration: NCT04607941
Publication Charmet T, Lancet Reg Health Eu, 2021
Dates: 2020-12-27 to 2021-05-04
Funding: Public/non profit (Institut Pasteur, Research & Action Emerging Infectious Diseases (REACTing), Fondation de France (Alliance “Tous unis contre le virus”).)
Conflict of interest: no COI (All authors have nothing to declare.)

Methods

Study design:Case-control
Description of participants: Adults in community with or without prior history of infection in France
Inclusion criteria:
  • Adults aged 18 or older
  • assessed between 14 February to 3 May, 2021
  • with an email address with the national health insurance agency.

Exclusion criteria:
  • Previous SARS-CoV-2 infection in past 2 months.

Follow-up duration (months): 4.27
Vaccines:
  • 2 doses of BNT162b2 or mRNA-1273
Variant description :
Variant name: Beta/Gamma
Evidence: Direct evidence (effectiveness determined by sequencing cases)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes
Data accessibility: The data that support the findings of this study are available from the Caisse Nationale d’Assurance Maladie, a national health insurance agency in France and from Ipsos, a French market research and public opinion specialist company. Restrictions apply to the availability of these data, which were used under authorized agreement for this study by the data protection authority Commission Nationale de l’In- formatique et des Libertes (CNIL). Access to these data would there- fore require prior authorization by the CNIL. (Corresponding author Dr. Fontanet: fontanet@pasteur.fr)
General comment